Effectiveness of Recombinant Human Growth Hormone (rhGH) in the Treatment of Patients with Cystic Fibrosis
Potential Harms of rhGH Treatment to Patients With CF: Glucose Control and CFRD (2)
Fasting blood glucose during treatment was elevated by 5.7mg/dL on average. Hemoglobin A1c was unaffected by rhGH treatment but the evidence quality is low. Evidence about random, postprandial and stimulated glucose levels is insufficient to estimate an effect.
Although CFRD developed in 3 patients during the course of treatment in trials where this event was monitored, the evidence is insufficient to evaluate the contribution of rhGH to these outcomes.
Keywords: A1c | CF | CF-related diabetes | CFRD | HGH | cystic fibrosis | glucose intolerance | hemoglobin A1c | human growth hormone | recombinant human growth hormone | rhGH | fasting blood glucose
- Phung OJ, Coleman CI, Baker EL, et al. Effectiveness of Recombinant Human Growth Hormone (rhGH) in the Treatment of Patients With Cystic Fibrosis. AHRQ Comparative Effectiveness Review No. 23 (Prepared by University of Connecticut-Hartford Hospital Evidence-based Practice Center under Contract No. 290-2007-10067-I). Rockville, MD: Agency for Healthcare Research and Quality; October 2010. AHRQ Publication No. 11-EHC003-EF.
Your slide tray is being processed.